Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Vaccines|February 27, 2020
Antigen-Based Nano-Immunotherapy Controls Parasite Persistence, Inflammatory and Oxidative Stress, and Cardiac Fibrosis, the Hallmarks of Chronic Chagas Cardiomyopathy, in A Mouse Model of Trypanosoma cruzi InfectionNandadeva Lokugamage, Subhadip Choudhuri, Carolina Davies, et al.
Emerging Microbes & Infections|April 24, 2026
Treatment with low-dose bicistronic immunotherapy mitigates parasite persistence and improves serological and cardiac outcomes in adult mice infected with Trypanosoma cruzi: comparative analysis with benznidazoleSubhadip Choudhuri, Allison Wyrick, Nandadeva Lokugamage, et al.
NPJ Vaccines|December 16, 2023
Subunit nanovaccine elicited T cell functional activation controls Trypanosoma cruzi mediated maternal and placental tissue damage and improves pregnancy outcomes in miceLizette Elaine Rios, Nandadeva Lokugamage, Subhadip Choudhuri, et al.
Virology|October 16, 2012
Rift Valley fever virus NSs inhibits host transcription independently of the degradation of dsRNA-dependent protein kinase PKRBirte Kalveram, Olga Lihoradova, Sabarish V Indran, et al.
Frontiers in Immunology|July 12, 2019
TcG2/TcG4 DNA Vaccine Induces Th1 Immunity Against Acute Trypanosoma cruzi Infection: Adjuvant and Antigenic Effects of Heterologous T. rangeli Booster ImmunizationShivali Gupta, Berenice Salgado-Jiménez, Nandadeva Lokugamage, et al.
JACC. Basic to Translational Science|April 22, 2026
RIG-I-Adjuvanted Immunogen Elicited T-Cell Immunity Controls Trypanosoma cruzi, Chagasic Cardiomyopathy, and Left Ventricular DysfunctionNandadeva Lokugamage, Allison Wyrick, Subhadip Choudhuri, et al.
Vaccine|October 25, 2017
Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strainHoai J Ly, Shoko Nishiyama, Nandadeva Lokugamage, et al.
Plos One|April 9, 2010
Rapid accumulation of virulent rift valley Fever virus in mice from an attenuated virus carrying a single nucleotide substitution in the m RNAJohn C Morrill, Tetsuro Ikegami, Naoko Yoshikawa-Iwata, et al.
Vaccine|September 3, 2013
Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calvesJohn C Morrill, Richard C Laughlin, Nandadeva Lokugamage, et al.
The Japanese Journal of Veterinary Research|April 5, 2007
A comparative epidemiological study of hantavirus infection in Japan and Far East RussiaHiroaki Kariwa, Kumari Lokugamage, Nandadeva Lokugamage, et al.
Pageof 4